| Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids KK Dijkstra, CM Cattaneo, F Weeber, M Chalabi, J van de Haar, ... Cell 174 (6), 1586-1598. e12, 2018 | 875 | 2018 |
| Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ... Nature medicine 25 (6), 920-928, 2019 | 760 | 2019 |
| High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (5), 661-672, 2021 | 749 | 2021 |
| Identification of CMTM6 and CMTM4 as PD-L1 protein regulators R Mezzadra, C Sun, LT Jae, R Gomez-Eerland, E De Vries, W Wu, ... Nature 549 (7670), 106-110, 2017 | 605 | 2017 |
| Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers W Scheper, S Kelderman, LF Fanchi, C Linnemann, G Bendle, ... Nature medicine 25 (1), 89-94, 2019 | 522 | 2019 |
| Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis MD Wellenstein, SB Coffelt, DEM Duits, MH van Miltenburg, M Slagter, ... Nature 572 (7770), 538-542, 2019 | 415 | 2019 |
| Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ... Cell 183 (3), 818-834. e13, 2020 | 377 | 2020 |
| Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): final response data stage I and first translational data. M Kok, L Voorwerk, H Horlings, K Sikorska, K van der Vijver, M Slagter, ... Journal of Clinical Oncology 36 (15_suppl), 1012-1012, 2018 | 48 | 2018 |
| Contact-dependent killing by cytotoxic T lymphocytes is insufficient for EL4 tumor regression in vivo RJ Beck, M Slagter, JB Beltman Cancer research 79 (13), 3406-3416, 2019 | 30 | 2019 |
| Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ... Nature medicine 25 (7), 1175-1175, 2019 | 14 | 2019 |
| Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 33 (11), 1204-1206, 2022 | 7 | 2022 |
| Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment ME Hoekstra, M Slagter, J Urbanus, M Toebes, N Slingerland, I de Rink, ... Cancer Cell 42 (1), 157-167. e9, 2024 | 5 | 2024 |
| Reply to:‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab … DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (9), 1194-1197, 2021 | 3 | 2021 |
| Spatial proximity of CD8 T cells to tumor cells as an independent biomarker for response to anti-PD-1 therapy. M Slagter, EA Rozeman, H Ding, JM Versluis, M Valenti, D Peters, ... Journal of Clinical Oncology 38 (15_suppl), 10038-10038, 2020 | 3 | 2020 |
| 31 Loss of P53 drives systemic neutrophilic inflammation in breast cancer M Wellenstein, S Coffelt, D Duits, M Van Miltenburg, M Slagter, I De Rink, ... ESMO Open 3, A14, 2018 | 1 | 2018 |
| Lack of detectable neoantigen depletion in treatment-naïve cancers M Slagter, LF Fanchi, MM van Buuren, A Velds, G Bounova, LFA Wessels, ... bioRxiv, 2023.06. 21.544805, 2023 | | 2023 |
| Abstract B022: Properties of T-cell-recognized neoantigens P Kvistborg, MM Buuren, D Philips, N Rooij, A Velds, S Behjati, M Braber, ... Cancer Immunology Research 7 (2_Supplement), B022-B022, 2019 | | 2019 |
| Benchmarking the Foreign Antigen Space of Human Malignancies M Slagter, LF Fanchi, MM Buuren, A Velds, JJA Calis, PC Schouten, ... Available at SSRN 3279415, 2018 | | 2018 |
| Breaking Insights MD Wellenstein, SB Coffelt, DEM Duits, MH van Miltenburg, M Slagter, ... | | |
